Marina

Title: Methods and Means for Producing Efficient Silencing Construct Using Recombinatorial Cloning
Patent Number: 8,877,435

NEW YORK (GenomeWeb) – Marina Biotech this week took another step toward reestablishing itself as a player in the nucleic acids drug sector, regaining compliance with US Securities and Exchange Commission financial reporting requirements with the submission of the requisite information for 2012,

Marina Biotech announced that it has appointed Daniel Geffken as its interim CFO as it works to restart drug-development operations after halting operations in mid-2012 amid a cash shortfall. Geffken is managing director at Danforth Advisors.

Having just closed its first financing transaction in two years, struggling Marina Biotech announced that it plans to continue looking beyond just RNAi and develop drugs using a number of different nucleic acid modalities.

Amid a resurgence of investor interest in RNAi as a therapeutic modality, two of the field's smaller players this week announced financing arrangements expected to help them reach key inflection points — news that prompted double-digit jumps in each company's share price.

Art Krieg has been named as CSO of RNA drug developer Sarepta Therapeutics.